Device Trial Radar · NCT04103749
Global Prospective Case Series Using a Single-Use Duodenoscope
Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
551
Actual
Start
Mar 22, 2021
Primary completion
Nov 23, 2022
Study completion Jan 5, 2023
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Confirm procedural performance of the ExaltTM Model D Single-Use Duodenoscope in Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and other duodenoscope-based procedures
Conditions
- Endoscopic Retrograde Cholangiopancreatography
Interventions
Exalt Model D Single-Use DuodenoscopeDevice
Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Successful ERCP ProcedureTime frame: Procedure success is assessed at the end of the procedure (within 24 hours on study day 1).
Locations
22 sites in 11 countries. Site status is shown where the registry gives one.
University of California Los Angeles Medical Center
Los Angeles, California
University of Chicago
Chicago, Illinois
Indianapolis University Hospital
Indianapolis, Indiana
19 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.